Milestone Pharmaceuticals Inc. MIST
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-9.77
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$63.1M | — | -$49.3M | $41.8M |
| 2024 | — | -$41.5M | — | -$28.9M | $13.1M |
| 2023 | — | -$59.7M | — | -$46.5M | $16.8M |
| 2022 | — | -$58.4M | — | -$52.7M | $66.3M |
| 2021 | — | -$42.9M | — | — | $112.6M |
| 2020 | — | -$50.0M | — | — | $143.1M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.77 (distress)
- Working capital / assets 0.862
- Retained earnings / assets -3.792
- EBIT / assets -0.547
- Equity / liabilities 0.582
Source: SEC EDGAR filings · CIK 0001408443 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.